Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by OSE Immunotherapeutics

OSE Immunotherapeutics provides an update on ongoing proceedings
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules
From OSE Immunotherapeutics
Via GlobeNewswire
ADJOURNMENT OF THE GENERAL MEETING INITALLY CONVENED ON JUNE 25, 2025
From OSE Immunotherapeutics
Via GlobeNewswire
UPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer Vaccine Tedopi® in Pancreatic Cancer and Non-Small Cell Lung Cancer
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab
From OSE Immunotherapeutics
Via GlobeNewswire
Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Highlights Abstracts Selected for Presentation at ASCO 2025
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral Presentation at 20th Congress of ECCO
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi®
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Strengthens Leadership and Executive Committee
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis
From OSE Immunotherapeutics
Via GlobeNewswire
Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco (June 18 – 21)
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s Growth
From OSE Immunotherapeutics
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.